Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.

Seminars in oncology - 1 Apr 2011

de Souza Jonas A, Olopade Olufunmilayo I

Abstract excerpt

The philosophy behind personalized medicine is that each patient has a unique biologic profile that should guide the choice of therapy, resulting in an improved treatment outcome, ideally with reduced toxicity. Thus, there has been increasing interest in identifying genetic variations that are predictive of a drug's efficacy or toxicity. Although it is one of the most effective drugs for treating breast cancer,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 CYP2D6 Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Antagonists

Share to Genotype

Share to Precision Medicine

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 21421116
DOI: 10.1053/j.seminoncol.2011.01.002
PMCID: PMC3769162

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine.PMID 21421116Read ↗

Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics.Semantic proximity Read ↗

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.Semantic proximity Read ↗

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.Semantic proximity Read ↗

Pharmacogenetics of endocrine therapy for breast cancer.Semantic proximity Read ↗

CYP2D6 genotyping and the pharmacogenetics of tamoxifen.Semantic proximity Read ↗

Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast CancerSemantic proximity Read ↗

CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.Semantic proximity Read ↗

Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Semantic proximity Read ↗

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.Semantic proximity Read ↗

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?Semantic proximity Read ↗

Should CYP2D6 be genotyped when treating with tamoxifen?Semantic proximity Read ↗

CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical RelevanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.